Search Results
Oct 17, 2025, 17:39 ET FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event
Christoffer Sho Togo Tullin (Global)+45 3079 [email protected]
More news about: Novo Nordisk
Oct 17, 2025, 17:15 ET FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event
[email protected] Christoffer Sho Togo Tullin (Global) +45 3079 1471
More news about: Novo Nordisk
Sep 29, 2025, 17:46 ET Novo Nordisk resubmits Awiqli® to the FDA with potential to be the first once-weekly basal insulin treatment for adults with type 2 diabetes
Christoffer Sho Togo Tullin (Global)+45 3079 1471
More news about: Novo Nordisk
Sep 29, 2025, 08:05 ET Novo Nordisk resubmits Awiqli® to the FDA with potential to be the first once-weekly basal insulin treatment for adults with type 2 diabetes
Christoffer Sho Togo Tullin (Global)+45 3079 1471
More news about: Novo Nordisk
Sep 29, 2025, 08:00 ET Novo Nordisk submits Biologics License Application (BLA) to FDA for Mim8; an investigational, prophylaxis treatment for people living with hemophilia A with or without inhibitors
Christoffer Sho Togo Tullin+45 3079 1471
More news about: Novo Nordisk
Sep 29, 2025, 08:00 ET Novo Nordisk submits Biologics License Application (BLA) to FDA for Mim8; an investigational, prophylaxis treatment for people living with hemophilia A with or without inhibitors
Christoffer Sho Togo Tullin+45 3079 1471
More news about: Novo Nordisk
Sep 25, 2025, 08:00 ET SUNSTONE HOTEL INVESTORS COMPLETES $1.35 BILLION AMENDED AND RESTATED CREDIT AGREEMENT
Sept. 25, 2025 /PRNewswire/ -- Sunstone Hotel Investors, Inc. (the "Company" or "Sunstone") (NYSE: SHO) announced that it has entered into a Third Amended and Restated Credit Agreement (the "Amended Credit Agreement") with an aggregate borrowing capacity
More news about: Sunstone Hotel Investors, Inc.
Sep 19, 2025, 08:00 ET SUNSTONE HOTEL INVESTORS SCHEDULES THIRD QUARTER 2025 EARNINGS RELEASE AND CONFERENCE CALL
Sept. 19, 2025 /PRNewswire/ -- Sunstone Hotel Investors, Inc. (the "Company" or "Sunstone") (NYSE: SHO) announced that it will report financial results for the third quarter 2025 on Friday, November 7, 2025, before the market
More news about: Sunstone Hotel Investors, Inc.